LGND News and Press, Ligand Pharmaceuticals Incorporated From 10/18/23

2023-10-18 11:05:36 ET More on Ligand Pharmaceuticals, Ovid Therapeutics, etc. Ovid Therapeutics: The GABA Gambit In Seizure Wars Ligand: Nothing Exciting Stands Out For further details see: Ligand Pharmaceuticals acquires 13% of soticlestat royalties from Ovid T...

Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid Ovid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash runway into 2026 while simultaneously retaining 87% of the interest in soticlestat Trans...

2023-10-03 17:46:09 ET More than 80 stocks were identified by Morgan Stanley as potentially having technical pressure due to tax loss selling. A Morgan Stanley U.S. Equity Strategy report, published on Monday, showed 81 stocks that could have performance pressures due to market selling ...

More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual health was ...

2023-09-27 13:47:17 ET More on Ligand Pharmaceuticals Ligand: Nothing Exciting Stands Out Ligand Pharmaceuticals Incorporated 2023 Q2 - Results - Earnings Call Presentation Ligand Pharmaceuticals Incorporated (LGND) Q2 2023 Earnings Call Transcript Ligand spi...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that it has closed the transaction to acquire assets of Novan, Inc. (“Novan”) following the offer it made on July 17, 2023. On July 17, 2023, Ligand offered $15 million to acquire all of the assets of Novan as well as to...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced the appointment of Martine Zimmermann, PharmD, to its Board of Directors as an independent director. Dr. Zimmermann brings 25 years of global experience in the pharmaceutical industry to Ligand’s board. “We are very ...

2023-09-25 17:28:21 ET More on Ligand Pharmaceuticals Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earnings data for Ligand Pharmaceuticals Financial information for Ligand Pharmaceuticals Novan craters as company files for bankrup...

2023-09-22 09:29:56 ET More on Jazz Pharma Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals Historical earnings data for Jazz Pharmaceuticals Financial information for Jazz Pharmaceuticals Jazz Pharmaceuticals: Depressed Valuation Opens Up Potentia...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that its partner Jazz Pharmaceuticals plc (Nasdaq: JAZZ), (“Jazz”) has been granted marketing authorization by the European Commission (EC) for Enrylaze ® (JZP458; a recombinant Erwinia asparaginase or crisantas...